MedTrace Logo

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

NCT02362620 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 402

Last updated 2020-01-27

No results posted yet for this study

Summary

PROSTAC is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with docetaxel or cabazitaxel

Conditions

Sponsors & Collaborators

  • Centro Nacional de Investigaciones Oncologicas CARLOS III

    lead OTHER

Principal Investigators

  • David Olmos, MD, PhD · Head of Prostate Cancer Clinical Research Unit CNIO

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-04-30
Completion
2020-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02362620 on ClinicalTrials.gov